This website is intended for healthcare professionals.

FERACCRU® relieved IDA in IBD patients who had previously failed on oral ferrous iron salts1

Study design

Mean Hb concentration from baseline to Week 12 (mean ± SD)1

A clinically relevant increase in Hb was observed as quickly as Week 4 with FERACCRU®1

86% of patients had a normal Hb level after 64 weeks’ treatment with FERACCRU®2

 

Study design

Mean Hb concentration over 64 weeks’ treatment (mean ± SD)2

FERACCRU® was an effective long-term treatment for IBD patients who had previously failed on oral ferrous iron salts1

FERACCRU® Real-world Effectiveness Study in Hospital practice (FRESH)3

Study design

In an observational cohort study of patients with inactive IBD and mild to moderate IDA in routine clinical practice, FERACCRU® effectively increased Hb and ferritin, and was generally well tolerated (n=59)3

  • 63% of patients had normalised Hb after 12 weeks (n=30)*3
  • The median time to Hb normalisation was 46 days (n=30)3
  • The most common AEs were abdominal pain or discomfort (15%), constipation (5%) and diarrhoea (3%)3
  • 20% of patients discontinued FERACCRU® due to AEs (n=59)3

*Normalised Hb was defined as ≥12 g/dL for women and ≥13 g/dL for men.
†Abdominal pain and discomfort included the combined categories of abdominal discomfort/distension, and abdominal pain and gastritis.

This observational study indicates that ferric maltol works effectively to increase Hb and ferritin and is generally well tolerated in patients with IBD and IDA treated in routine clinical practice, supporting the findings of randomised controlled trials.

CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CKD, chronic kidney disease; Hb, haemoglobin; IBD, inflammatory bowel disease; IDA, iron deficiency anaemia; QoL, quality of life; SCCAI, Simple Clinical Colitis Activity Index; SD, standard deviation; TSAT, transferrin saturation; UC, ulcerative colitis.

References:

  1. Gasche C, et al. Inflamm Bowel Dis 2015;21(3):579–588.
  2. Schmidt C, et al. Aliment Pharmacol Ther 2016;44(3):259–270.
  3. Cummings F, et al. BMJ Open Gastroenterol 2021;8(1):e000530.

Hi, I'm Eric.
Click here to ask me a question about FERACCRU®